nemolizumab
aikido pharmaceuticals,galderma
['nemolizumab', 'olympia 2', 'derm', 'spherix']
spherix s dermatology franchise leader gianna melendez speaks with at the 2023 aad annual meeting, announcing positive news on the phase 3 data from the olympia 2 study on nemolizumab monotherapy for the treatment of pn #prurigo in #primetime 
Spherix Global Insights is a leading provider of market research, business intelligence & advisory services to the global dermatology & life sciences industry.